← Leaderboards
Charles L Shapiro
Ohio State University
$2,281,818
Attributed
$3,215,935
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $875.4K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$3,215,935 · 7
By mechanism
U01$1,868,235 · 1
R21$632,288 · 1
P30$582,712 · 2
M01$132,700 · 3
Top collaborators
- Kay Huebner4 shared
Most similar at Ohio State University
Same institution · by research overlap
- Michael A Caligiuri$65,062,344
- Nilsa Del Carmen Ramirez$84,826,096
- Jessie L.-S. Au$10,705,345
- Electra D. Paskett$38,729,537
- Claire F Verschraegen$7,194,564
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsHuman SubjectProgramsMonitorPharmacistsProtocols DocumentationQuality ControlMemberReview CommitteeEnsureNursing ResearchExperimental DesignsClinical ProtocolsResearch PersonnelExpectationResourcesClinical TrialsTreatment PlanningBaseExclusion CriteriaCancer Center Support GrantDrug IndustryWritingLeft
Grant awards (22)
Protocol Review and Monitoring System$48,365
P30 · FY2015 · CA · contact PI
Protocol Review and Monitoring System$49,000
P30 · FY2014 · CA · contact PI
MicroRNA profiles of TN breast cancer to define subgroups and targets for therapy$411,074
U01 · FY2013 · CA
Protocol Review and Monitoring System$47,231
P30 · FY2013 · CA · contact PI
MicroRNA profiles of TN breast cancer to define subgroups and targets for therapy$443,720
U01 · FY2012 · CA
Protocol Review and Monitoring System$50,518
P30 · FY2012 · CA · contact PI
MicroRNA profiles of TN breast cancer to define subgroups and targets for therapy$465,130
U01 · FY2011 · CA
Novel Markers of Anthracycline-induced Myocardial Damage$305,198
R21 · FY2011 · CA · contact PI
MicroRNA profiles of TN breast cancer to define subgroups and targets for therapy$548,311
U01 · FY2010 · CA
Novel Markers of Anthracycline-induced Myocardial Damage$327,090
R21 · FY2010 · CA · contact PI
Protocal Review and Monitoring System$103,321
P30 · FY2009 · CA · contact PI
Protocal Review and Monitoring System$97,872
P30 · FY2008 · CA · contact PI
Protocal Review and Monitoring System$86,841
P30 · FY2007 · CA · contact PI
Protocal Review and Monitoring System$50,518
P30 · FY2006 · CA · contact PI
Protocal Review and Monitoring System$49,046
P30 · FY2005 · CA
A PHASE I/II STUDY OF SURAMIN IN COMBINATION WITH PACLITAXEL IN BREAST CANCER$14,006
M01 · FY2005 · RR
PHASE I STUDY OF PS-341 WITH PACLITAXEL IN METASTATIC SOLID TUMORS$9,337
M01 · FY2005 · RR
Phase I/II Study of Suramin/ Paclitaxel in Breast Cancer$65,252
M01 · FY2004 · RR
Phase I study of PS-341 with paclitaxel in metastatic solid tumors$44,105
M01 · FY2004 · RR
PHASE I TRIAL OF HERCEPTIN AND INTERLEUKIN 12$0
M01 · FY2001 · RR
PHASE I TRIAL OF HERCEPTIN AND INTERLEUKIN 12$0
M01 · FY2000 · RR
PHASE I TRIAL OF HERCEPTIN AND INTERLEUKIN 12$0
M01 · FY2000 · RR